rectal and Rectal sigmoid junction adenocarcinoma
Conditions
Interventions
Case series:neoadjuvant sequential therapy
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
15 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-75 years; 2. ASA anesthesia grade I to III; 3. pathologically confirmed adenocarcinoma; 4. the lower margin of the tumor was 12cm or more from the anal margin and the upper segment of the rectum was located at the junction of straight b (MRI or pelvic CT images were located 5cm above and below the upper margin of the promontory of the sacrum and the symphysis pubis in sagittal position); 5. the clinical stage was cT4bNanyM0/ cT3-4aN2m0, or EMVI (+), or the maximum diameter of the tumor >=5cm; 6. patients who have not received radiotherapy, chemotherapy and surgery; 7. liver, kidney and other organs of patients function well, and patients can withstand radiotherapy and chemotherapy and surgery; 8. the patients and their families can understand the study plan and participate in the study voluntarily, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. patients with multiple primary colorectal cancer; 2. patients with a history of other malignant tumors in the past 5 years (excluding cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer or surgically excised breast ductal carcinoma in situ); 3. patients complicated with intestinal perforation, gastrointestinal bleeding, and unrelieved intestinal obstruction (except those who have undergone rerourostomy or have been placed with intestinal stent to remove the obstruction) need emergency surgery; 4. patients with severe infection; 5. pregnant or nursing women; 6. have a history of serious mental illness; 7.participated in other clinical researchers for nearly 3 months; 8.those who have contraindications of chemoradiotherapy or surgical treatment; 9. any other circumstances deemed inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events during radiotherapy/chemotherapy;CRM and safe margin of distal clearance;Perioperative complication rate;3-year disease free survival; | — |
Countries
China
Contacts
Public ContactWu Bin
Peking Union Medical College Hospital
Outcome results
None listed